Healthcare
NewAmsterdam Pharma Company N.V.(NAMS)
Live Price
Offline$29.83
-1.06% today
1Y Change
+76.86%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $3.27B
- Revenue Growth
- -50.6%
- EPS Growth
- +31.6%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
NewAmsterdam Pharma Company N.V. (NAMS) is a Healthcare stock with a market cap of $3.27B and listed on NASDAQ. The stock last traded around $29.83 and up 76.9% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of -50.6%, EPS growth of +31.6%, a dividend yield of 0.0%. What stands out right now is revenue -50.6%, EPS +31.6%, free cash flow +7.0% with operating margin -1002.9% and ROIC -33.0%. Valuation already assumes a fairly strong business story at price/sales 145.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NAMS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-50.6% vs +7.6% peer median
Operating Margin
Below sector median
-1002.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -50.6% and EPS is at +31.6%, with operating margin around -1002.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.9% | -3.1% | -17.6% |
2026 Feb 18, 2026 | -57.5% | -3.2% | -2.1% | -17.7% |
2025 Nov 5, 2025 | -7.9% | -2.8% | +0.5% | -6.0% |
Benchmark Edge
NAMS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NAMS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NAMS Max Drawdown
-31.41%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NAMS and SPY.
Company Overview
NewAmsterdam Pharma Company N.V.
NASDAQ Capital Market
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
- Leadership
- Michael Harvey Davidson Facp.
- IPO Date
- Feb 9, 2021
- Employees
- 68
- Street Address
- Gooimeer 2-35
- Mailing
- Naarden, 1411 DC
- Region
- Naarden, NL
- Reporting Currency
- USD
- Investor Line
- 31 35 206 2971
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 145.3
- Price/Book
- 4.8
Growth
- Revenue
- -50.6%
- EPS
- +31.6%
- Free Cash Flow
- +7.0%
Profitability
- Gross Margin
- 99.7%
- Operating Margin
- -1002.9%
- Net Margin
- -905.7%
- ROE
- -27.5%
- ROIC
- -33.0%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 7.88
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.